

		•	
Day 1	Friday, 22 May 15		
08:00	Registration		
08:30	Welcome	Paul Werker	
08:35		Jos Aartsen CEO UMCG	
08:40		Wolfgang Wach & Charles E	aton
08:45	Lecture: Treatment of Dupuytren in	Zolt Szabo	Chair : Paul
	different countries and the role of FESSH		Werker
	and IFSSH in promoting knowledge for		
	hand surgeons		
09:05	Session 1: Epidemiology & Patients Views	Chair : Bert Reichert & Zsolt	Szabo
09:05	The epidemiology of surgical intervention	Joe Dias	
	for Dupuytren's Contracture in England		
09:11	Favorite Options of German Hand Surgeons	Bert Reichert	
	in the Treatment of Dupuytren Disease		
09:17	Trends in Dupuytren's Treatment in the	Philip Blazar	
09.17	United States	Fillip blazai	
09:23	Discussion		
09:38	The Patient's View and Needs – An	Wolfgang Wach	
	International Survey: Dupuytren Disease		
09:44	Patients' preferences for treatment for	Hester Kan	
	Dupuytren's disease: a Discrete Choice		
	Experiment		
09:50	Discussion		
10:00	Coffee Break	D. 11000	Chair Baria
10:30	Lecture : The extra-cellular matrix in	David O'Gorman	Chair: Boris
	Dupuytren's disease		Hinz & Ruud Bank
10:50	Session 2: Cellular and extracellular	Chair : Boris Hinz & Ruud Ba	
	events		
10:50	PDGFR-β targeted modified interferon	Marianna Kruithof-de Julio	
	gamma in Dupuytren's disease		
10:56	Wnt pathway in Dupuytren disease,	Marike van Beuge	
	connecting pro-fibrotic signals		
11:02	Biomarkers of post-surgical outcome in	lan Clark	
11,00	Dupuytren's disease	Jagdoon Nanchahal	
11:08	Tumour necrosis factor (TNF) as a	Jagdeep Nanchahal	
	therapeutic target in Dupuytren's disease		

Splinting confers no benefit Splinting is beneficial Audience response Coffee Break Lecture: Collagenase Treatment - Journey from Bench to Current Advanced Clinical Use Session 4: Collagenase Injection		rand
Splinting is beneficial Audience response Coffee Break Lecture: Collagenase Treatment - Journey from Bench to Current	Wolfgang Wach Larry Hurst Chair Coler	man &
Splinting is beneficial Audience response Coffee Break	Wolfgang Wach	
Splinting is beneficial Audience response	•	
Splinting is beneficial	•	
•	•	
Chlinting conforcing honofit	Adrian Chainawski	
Dupuytren Contracture		
Controversies 2: The benefit of splinting for	Chair : Ilse Degreef	
elderly field hockey players and controls Discussion		
disease and diabetes The association between vibration and	Dieuwke Broekstra	
	Dieuwke Broekstra	
Discussion	D'e la Day La	
Identification and characterization of functional genetic variants in Dupuytren's Disease	Juanjiangmeng Du	
GWAS identifies new significant loci in patients with Dupuytren's disease	Kerstin Becker	
Genetic Susceptibility Variants for Dupuytren's Disease	Karatin Daalaan	
Session 3: Genetics & Associations A Large European Genome-wide	Chair : Roel Ophoff & Hans Hennie Michael Ng	es
Lecture : Genetics in Dupuytren Disease	Roel Ophoff Chair Henr	: Hans nies
Audience response		
Passive Contracture	Charles Eaton	
Active Contracture	Jagdeep Nanchahal	
Dupuytren Disease; active or	Chair : David O'Gorman	
Discussion	01 : 5 :1010	
	Controversies 1: Pathogenesis of Dupuytren Disease; active or passive contracture? Active Contracture Passive Contracture Audience response Lunch Lecture: Genetics in Dupuytren Disease Session 3: Genetics & Associations A Large European Genome-wide Association Study Reveals Multiple New Genetic Susceptibility Variants for Dupuytren's Disease Meta-analysis of genome-wide imputed GWAS identifies new significant loci in patients with Dupuytren's disease Identification and characterization of functional genetic variants in Dupuytren's Disease Discussion A systematic review and meta-analysis on the association between Dupuytren disease and diabetes The association between vibration and Dupuytren disease: a comparison between elderly field hockey players and controls Discussion Controversies 2: The benefit of splinting for	Controversies 1: Pathogenesis of Dupuytren Disease; active or passive contracture? Active Contracture Passive Contracture Audience response Lunch Lecture: Genetics in Dupuytren Disease A Large European Genome-wide Genetic Susceptibility Variants for Dupuytren's Disease Meta-analysis of genome-wide imputed GWAS identifies new significant loci in patients with Dupuytren's disease Identification and characterization of functional genetic variants in Dupuytren's Disease Discussion A systematic review and meta-analysis on the association between Dupuytren disease and diabetes The association between vibration and Dupuytren disease: a comparison between elderly field hockey players and controls Discussion Controversies 2: The benefit of splinting for Chair: Ilse Degreef

1	15:41	Efficacy of using local anesthesia before collagenase injection in reducing overall pain experience in patients treated for Dupuytren's contracture: A quasirandomized study	Jesper Nordenskjöld
1	15:47	Effect of Delayed Finger Extension on the Efficacy and Safety of Collagenase Clostridium Histolyticum Treatment for Dupuytren's Contracture	Gary M. Pess
1	15:53	The use of a dynamic dorsal splint for Dupuytren Rehabilitation after collagenase	Massimo Corain
1	15:59	Discussion	
1	L6:19	Dupuytren Award 2014	Wolfgang Wach & Paul Werker
1	L6:24	Treatment with Collagenase Clostridium Histolyticum: Five-Year CORDLESS Data	Clayton A. Peimer
1	L6:30	Prospective Multicenter, Multinational Study to Evaluate the Safety and Efficacy of Concurrent Collagenase Clostridium Histolyticum Injections to Treat Two Dupuytren's Contractures in the Same Hand	Marie Badalamente
1	16:36	An Open-label, Controlled Phase 2a Study of the Safety and Efficacy of Injectable Collagenase Clostridium Histolyticum (CCH) in Patients with Adhesive Capsulitis (Frozen Shoulder)	Marie Badalamente
1	16:42	Collagenase- what we may never know- a discussion paper	David Warwick
1	L6:48	Discussion	

17:04	Controversies 3: The best minimally	Chair : Charles Eaton
	invasive treatment for Dupuytren Disease:	
	PNF or Collagenase?	
17:06	Percutaneous Needle Fasciotomy	Paul Werker
17:11	Collagenase	David Warwick
17:16	Audience Response	
17:34		

Day 2	Saturday, 23 May 15	
08:00	Registration	
08:30	Session 5: Assessment/ Percutaneous Needle Fasciotomy	Chair : Gary Pess & Ulrich Lanz
08:30	MCID for the Patient Evaluation Measure as a Patient Rated Outcome Measure for	Joe Dias
08:36	Dupuytren Contracture Predictors of Satisfaction with Hand Function in Patients with Dupuytren's Disease	Chao Zhou
08:42	URAMS as a PROM for Dupuytren Contracture Patients	Joe Dias
08:48	Discussion	
09:03	Tips and Pearls for Percutaneous Needle Fasciotomy and Collagenase - A Ten Year Personal Experience	Gary Pess
09:09	Percutaneous Needle Fasciotomy for secondary or higher recurrence in Dupuytren's disease	Margot Vlot
09:15	Extensive Percutaneous Aponeurotomy and Lipofilling versus Limited Fasciectomy in Patients with Primary Dupuytren's Contracture; a Randomized Controlled Trial	Steven Hovius
09:21	Discussion	
09:37	Controversies 4: How to treat severe PIP contractures: minimally invasive of surgically?	Chair: Joe Dias
09:41	Minimally invasive methods	Clayton Peimer
09:46	Surgical correction	Caroline Leclercq
09:51	Audience response	
10:15	Coffee Break	

10:45	Lecture: Treatment of Dupuytren Disease: Where are we now	David Elliot	Chair : Caroline Leclercq
11:05	Session 6: Comparative Studies/ Recurrence	Chair : Caroline Leclercq & D	avid Elliot
11:05	Steroid injection and needle aponeurotomy for Dupuytren disease: long-term follow-up of a randomized controlled trial	Paul Binhammer	
11:11	Minimal invasive treatment of Duputren: Collagenase vs. PNF	Eva-Maria Baur	
11:17	Collagenase Clostridium Histolyticum versus Partial Fasciectomy for Dupuytren's contracture: Early Outcomes From A Multicenter Propensity-Score Matched Study	Chao Zhou	
11:23	Discussion		
11:35	Actual Indications of Continuous Extension Technique (TEC) For Severe Dupuytren Disease	Jane C Messina	
11:41	Preliminary soft-tissue distraction versus checkrein ligament release after fasciectomy in the treatment of Dupuytren proximal interphalangeal joint contractures	Atanu Biswas	
11:47	Discussion		
11:55	The Palmodigital Spiralling Sheath	Rinze Lykele Zwanenburg	
12:01	Clusters in short term disease course in participants with primary Dupuytren Disease	Rosanne Lanting	
12:07	Discussion		
12:15	Recurrence after Treatment for Dupuytren's Disease; A consensus-based definition	Ruud Selles	
12:21	Recurrence after Dupuytren's disease: the time factor	Caroline Leclercq	
12:27	Is Recurrence of Dupuytren Disease Prevented by Full-Thickness Grafting Surgery?	Ilse Degreef	
12:33	Discussion		
12:45	Lunch		
13:45	Housekeeping		
13:50	Lecture: Radiotherapy for Early Stage Dupuytren and Ledderhose Disease	Heinrich Seegenschmiedt	Chair : Richard Shaffer & Ruud Selles

Session 7: Related disease & Other	Chair: Richard Shaffer & Ruud Selles
Treatments	
A Systematic Review Of Non-Surgical	Catherine Ball
Treatments For Early Dupuytren's Disease	
The Patient's View and Needs – An	Gary Manley
International Survey: Ledderhose Disease	
Discussion	
Use of Acellular Dermal Matrix in	Gloria Sue
Dupuytren Disease	
Tension versus compression on Dupuytren	Ilse Degreef
Discussion	
Lecture: Peyronie's Disease Treatment:	Mels van Driel
The State of the Art	
Coffee Break	
Focus on Research: Introduction to the	Joe Dias
symposia	
Basic Research: important prerequisites	Chair : David O'Gorman
for future studies	
Clinical Research: international	Chair : Marie Badalamente
collaboration to execute high powered	
clinical trials	
Close	Wolfgang Wach, Charles Eaton & Paul Werker
	Treatments A Systematic Review Of Non-Surgical Treatments For Early Dupuytren's Disease The Patient's View and Needs – An International Survey: Ledderhose Disease Discussion Use of Acellular Dermal Matrix in Dupuytren Disease Tension versus compression on Dupuytren Discussion Lecture: Peyronie's Disease Treatment: The State of the Art Coffee Break Focus on Research: Introduction to the symposia Basic Research: important prerequisites for future studies Clinical Research: international collaboration to execute high powered clinical trials

	Posters	
1	Elevated cAMP Inhibits both Basal- and	Latha Satish
	PDGF-Induced Cell Migration and	
	Contraction in Dupuytren's Contracture- Derived Fibroblasts	
2	Correlation of function with deformity in	David Warwick
	Dupuytren's Disease- the condition specific	
	Southampton Scoring Scheme outperforms	
	the generic QuickDASH	
3	Tonometry as an outcome measure for the	Catherine Ball
4	treatment of Dupuytren's disease Intra- and inter-observer agreement on	Dieuwke Broekstra
4	diagnosis and measurements of Dupuytren	Dieuwe Dioevstia
	disease severity	
5	Variation in range of movement reporting	Anna Pratt
	in Dupuytren's disease	
6	Experience of Treating Patients with Stage	Andrey Zhigalo
7	IV Dupuytren Contracture Six Years Experience of Using Needle	Andrey Zhigalo
,	Aponeurotomy when Treating Patients	Andrey Zingalo
	with Dupuytren's Disease	
8	YAP1 is a driver of myofibroblast	Bram Piersma
	differentiation in normal and Dupuytren's	
0	fibroblasts Clinical Validation of Pharmacoeconomic	Defect Conjuga
9	Model in Dupuytren Contracture	Rafael Sanjuan
10	Collagenase versus Fasciectomy in	Rafael Sanjuan
	Dupuytren Dissease: Cost-Utility Analysis	
11	Origin of Dupuytren's myofibroblasts in an	Sofia Karkampouna
	ex vivo tissue culture system	